Indian Journal of Health Care, Medical & Pharmacy Practice (Vol 7, Issue 3-4, Oct-Dec 2026)
Home page of the journal: https://ijhmp.com/Home

Research Article

EFFECT OF OMEGA-3 FATTY ACID SUPPLEMENTATION ON DEPRESSION: CLINICAL EVIDENCE, MECHANISMS, DOSE OPTIMIZATION AND PHARMACY PRACTICE PERSPECTIVES

Ajeet Singh[1]*, Dr. Manju Pandey[1], Mayank Kumar[1], Amit Gupta[1], Shiekh Aman[1], Apurwa Singh[1]

[1]Institute of Pharmacy, Shri Ramswaroop Memorial University, Lucknow–Deva Road, Lucknow, Uttar Pradesh, India.

Corresponding Author*: Ajeet Singh, Institute of Pharmacy, Shri Ramswaroop Memorial University, Lucknow–Deva Road, Lucknow, Uttar Pradesh, India.

Email ID: ajeetphd2024@gmail.com

Orcid ID: https://orcid.org/0009-0000-0775-329X

DOI: https://doi.org/10.59551/IJHMP/25832069/2026.7.3/4.122

How to cite this article: Singh A, Pandey M, Kumar M et al. Effect of Omega-3 Fatty Acid Supplementation on Depression: Clinical Evidence, Mechanisms, Dose Optimization and Pharmacy Practice Perspectives. *Indian J. Health Care, Med. Pharm. Pract.* 2026;7(3-4):173-188.


COPYRIGHT@ 2026, IJHMP | This work is licensed under a Creative Commons Attribution 4.0 International Licence

Received: 07 Sept, 2026, Decision for Acceptance: 14 Oct, 2026

ABSTRACT

Depression is a common and disabling mental disorder in which biological, psychological and social factors interact. Current evidence indicates that nutritional status, inflammation, neuronal membrane composition and metabolic signaling may contribute to differences in depression risk and treatment response. Omega-3 polyunsaturated fatty acids (n-3 PUFAs), particularly eicosatetraenoic acid (EPA) and docosahexaenoic acid (DHA), have therefore been investigated as dietary supplements and adjunctive treatments for depressive symptoms. This review summarizes the biological rationale, proposed mechanisms, clinical evidence, dose and formulation considerations, safety profile, special-population data and implications for pharmacy practice. Evidence from randomized trials and systematic reviews is heterogeneous. A 2021 Cochrane review concluded that omega-3 supplementation probably has a small-to-modest effect on depressive symptoms compared with placebo, but the clinical significance remained uncertain. A 2024 dose-response meta-analysis of 67 randomized trials reported improvement in depressive symptoms, with the largest estimated benefit in patients with established depression around 1.5 g/day of total n-3 fatty acids, while prevention of incident depression in the general population was not demonstrated with comparable certainty . A 2025 meta-analysis of 36 studies found a small overall symptom benefit, but response and remission rates were not clearly superior to placebo and substantial heterogeneity and publication bias were observed. EPA-predominant formulations appear more consistently associated with antidepressant benefit than DHA-predominant formulations, especially as adjuncts to antidepressant medication, although the ideal dose and EPA:DHA ratio remain unsettled. Mechanistically, omega-3 fatty acids may influence inflammatory signaling, eicosanoid and specialized pro-resolving mediator pathways, cell-membrane fluidity, monoaminergic neurotransmission, HPA-axis regulation, oxidative stress, neuroplasticity and BDNF-related signaling. Adverse effects are generally mild, but gastrointestinal symptoms, bleeding considerations with anticoagulants, and a possible increase in atrial fibrillation risk at high cardiovascular doses should be considered. Overall, omega-3 supplementation is best viewed as a potential adjunct rather than a replacement for evidence-based depression care. Future research should use standardized EPA/DHA preparations, clinically meaningful endpoints, baseline omega-3 status, inflammatory biomarkers, longer follow-up and adequately powered precision-medicine designs.

KEYWORDS: Omega-3 Fatty Acids, Eicosatetraenoic Acid, Docosahexaenoic Acid, Depression.



Geographical Abstract

Introduction

Depression is more than a short-lived emotional response. The World Health Organization reported that depression affects a substantial proportion of the global population and is associated with impairment in relationships, education, employment, sleep, appetite, cognition and physical health, as well as increased suicide risk.[1] Effective psychological treatments exist and medicines may be used according to severity and clinical context.[1,2] These facts create an ongoing need for treatments that are effective, acceptable, safe and accessible. Pharmacological treatment of depression commonly targets monoaminergic signaling, but the biology of depression extends beyond serotonin, norepinephrine and dopamine. Altered immune signaling, oxidative stress, HPA-axis activity, membrane lipid composition, neuroplasticity, metabolic status and gut-brain communication have been investigated as interconnected contributors to depressive illness.[9,24] This broader model has helped nutritional psychiatry develop from observational associations toward testable adjunctive interventions.[5,33] Omega-3 PUFAs are essential dietary lipids. EPA and DHA are found mainly in marine foods, while alpha-linolenic acid (ALA) is a plant-derived omega-3 fatty acid. Human conversion of ALA to EPA and DHA is limited, so direct dietary intake of EPA/DHA or supplementation may produce greater increases in circulating and tissue long-chain omega-3 concentrations than relying on ALA alone.[31] The brain contains substantial DHA and uses long-chain fatty acids as structural components of neuronal membranes. EPA is less abundant structurally but is biologically active through lipid mediators and inflammatory signaling.[9,31]The initial interest in omega-3s and depression arose from ecological and observational observations that higher fish intake appeared to correlate with lower depression prevalence. These observations stimulated randomized trials with fish oil, purified EPA, DHA and mixed EPA/DHA formulations. The clinical literature has since become large but inconsistent. Differences in diagnosis, baseline omega-3 status, placebo oil, EPA:DHA ratio, dosage, treatment duration, concomitant antidepressants, age, inflammation and outcome scales can materially change the observed effect.[13,14,33] The purpose of this review is to place the evidence into a practical B.Pharm perspective. The focus is not to present omega-3 supplements as a cure for depression, but to explain what is known, what remains uncertain, how formulations differ, and what a pharmacist should consider when supporting safe, evidence-informed use.[2,5]

Objectives of the Review

The objectives of this review are to:

1. Explain the chemistry, major dietary sources and biological functions of EPA, DHA and other omega-3 fatty acids.
2. Summarize pathophysiological features of depression that may be influenced by omega-3 fatty acids.
3. Discuss proposed antidepressant mechanisms involving inflammation, neurotransmitters, neuroplasticity, oxidative stress, HPA-axis function and the gut-brain axis.
4. Critically review clinical trials, systematic reviews and meta-analyses evaluating omega-3 supplementation for depression.
5. Compare evidence for EPA-predominant, DHA-predominant and mixed EPA/DHA formulations and

discuss dose considerations.
6. Review adverse effects, drug interactions, high-dose safety issues and monitoring considerations.
7. Highlight special-population evidence and the role of pharmacists in formulation selection, counselling, adherence and monitoring.
8. Identify important gaps for future clinical and pharmaceutical research.

Omega 3 Fatty Acids: Chemistry, Types and Sources

Omega-3 fatty acids are polyunsaturated fatty acids characterized by the location of the first carbon-carbon double bond three carbons from the methyl (omega) end. Their degree of unsaturation influences membrane structure, lipid mediator production and susceptibility to oxidation. The main omega-3 fatty acids relevant to nutrition and psychiatry are ALA (18:3 n-3), EPA (20:5 n-3), DPA n-3 (22:5 n-3) and DHA (22:6 n-3).[9,31] EPA and DHA can be obtained from fish and fish oil, krill oil and purified concentrates; algal oils are important non-fish sources of DHA and some products provide EPA as well.[31] Pharmaceutical and supplement products may differ substantially in chemical form, concentration, oxidation status, capsule size, excipients and third-party quality testing. A label stating "1000 mg fish oil" does not necessarily mean 1000 mg of EPA+DHA. For clinical interpretation, the amount of actual EPA and DHA should be read separately.[31] Supplement products may use triglyceride, re-esterified triglyceride, phospholipid or ethyl ester forms. Differences in absorption can occur depending on food intake and chemical form, but clinical depression trials have generally been more influenced by EPA/DHA content and ratio than by the label term "fish oil" [5,31]. Oxidation is an important quality issue because highly unsaturated fatty acids are chemically vulnerable to lipid peroxidation. Product freshness, storage, packaging and manufacturer quality controls therefore matter.[31]

Table 1: Major Omega-3 Fatty Acids Relevant to Depression

Fatty acid	Common sources	Main biological component/relevance	Relevance to depression research
ALA	Flaxseed, chia, walnuts, some plant oils	Essential plant-derived omega-3; precursor of longer-chain forms	Useful for dietary adequacy, but conversion to EPA/DHA is limited[31]
EPA	Fatty fish, fish oil, algal or concentrated preparations	Precursor for lipid mediators; important role in inflammatory signaling	Most consistently associated with adjunctive antidepressant effects[5,13,14]
DHA	Fatty fish, fish oil, algae	Major structural component of brain and retinal membranes	Important for neuronal membrane function; clinical antidepressant results are less consistent when used alone[9,15]
DPA n-3	Marine foods and endogenous metabolism	Intermediate long-chain omega-3 with signaling roles	Limited direct depression trial evidence[31]

Table 2: Chemical and Clinical Characteristics of Major Omega-3 Fatty Acids

Omega-3 Fatty Acid	Chemical Name	Lipid Notation	No. of Carbon Atoms	No. of Double Bonds	Double-Bond Position*	Major Sources	Key Chemical/Clinical Relevance
ALA	α-Linolenic acid	**18:3 n-3**	18	3	ω-3	Flaxseed, chia seeds, walnuts, vegetable oils	Essential dietary omega-3 fatty acid; precursor of EPA and DHA, but conversion is limited
EPA	Eicosap-entaenoic acid	**20:5 n-3**	20	5	ω-3	Fish, fish oil, krill oil, purified concentrates, some algal oils	Highly unsaturated fatty acid; important in lipid mediator production and extensively studied for depressive symptoms
DPA n-3	Docosap-entaenoic acid	**22:5 n-3**	22	5	ω-3	Fish and marine oils	Intermediate long-chain omega-3 fatty acid involved in lipid metabolism and membrane biology
DHA	Docosah-exaenoic acid	**22:6 n-3**	22	6	ω-3	Fatty fish, fish oil, krill oil, algal oil	Highly unsaturated fatty acid; important structural component of neuronal and cellular membranes

ISSN 2583-2069

Table 3: Key Parameters and Considerations in Omega-3 Fatty Acid Formulations

Parameter	Description	Importance
Polyunsaturated fatty acids (PUFAs)	Fatty acids containing multiple carbon–carbon double bonds	Their degree of unsaturation affects membrane fluidity, lipid signaling and oxidative stability
Degree of unsaturation	Determined by the number of C=C double bonds	Greater unsaturation generally increases susceptibility to lipid oxidation
EPA + DHA content	Actual quantity of EPA and DHA present in a supplement	More clinically meaningful than the total amount of "fish oil" stated on the label
Triglyceride (TG) form	Omega-3 fatty acids esterified to glycerol	Common dietary/supplement form
Re-esterified triglyceride (rTG) form	Concentrated omega-3 fatty acids reattached to a glycerol backbone	Used in concentrated omega-3 formulations
Ethyl ester (EE) form	EPA/DHA esterified with ethanol	Common in pharmaceutical-grade and concentrated omega-3 preparations
Phospholipid form	Omega-3 fatty acids incorporated into phospholipid molecules	Found particularly in some marine sources such as krill oil
Lipid mediators	Bioactive molecules derived from polyunsaturated fatty acids	May influence inflammatory and neuronal signaling
Lipid peroxidation	Oxidative degradation of unsaturated fatty acids	Can compromise product quality and generate oxidation products
Oxidation susceptibility	Increases with the number of double bonds	DHA, with six double bonds, is particularly vulnerable to oxidation
C hemical stability	Influenced by oxygen, light, temperature and storage conditions	Proper packaging and storage help maintain omega-3 quality
EPA:DHA ratio	Relative proportion of EPA and DHA in a formulation	Important consideration when interpreting clinical trials of depression
Concentration	Amount of EPA and/or DHA per capsule or dose	Two products containing the same total fish-oil weight may provide very different EPA+DHA doses
Excipients	Additional ingredients used in supplement formulations	May influence dosage form characteristics and stability
Third-party testing	Independent assessment of product quality and purity	Can provide information about potency, contaminants and oxidation status

Biological Mechanisms Relevant to Depression

Table 4: Potential Interactions of Omega-3 Fatty Acids with Antidepressant and Other Psychotropic Treatments

Mechanism	Role in depression	Proposed omega-3 action
Inflammation	Elevated inflammatory cytokines may contribute to depressive symptoms	EPA/DHA → lipid mediators and specialized pro-resolving mediators; modulation of inflammatory signaling[9,10]
Neurotransmitters	Altered serotonin, dopamine, norepinephrine and glutamate/GABA signaling	Effects on membrane fluidity, receptor function and intracellular signaling[9,13]
Synaptic plasticity	Reduced neuroplasticity and BDNF signaling may contribute to depressive s58symptoms	Possible increase in BDNF-related signaling and neuroplasticity[11,12]
HPA axis	Cortisol and stress-response dysregulation	Possible modulation of stress response[9,24]
Gut-brain axis	Dysbiosis, intestinal barrier dysfunction and immune activation may contribute to symptoms	Possible effects on microbiota, gut barrier and inflammatory signaling[24]

Mechanism	Role in depression	Proposed omega-3 action
Oxidative stress	Oxidative damage may contribute to neuronal dysfunction	Modulation of redox signaling and antioxidant responses, although omega-3 PUFAs themselves are oxidation-sensitive [9,31]

Depression: Pathophysiology Relevant to Omega-3




Figure 1: Proposed mechanism of action of omega-3 fatty acids in depression: modulation of inflammation, neurotransmitter systems, HPA-axis and stress biology, oxidative stress and mitochondrial function, neuroplasticity, and BDNF-mediated synaptic plasticity

Inflammation and Immune Signaling

A substantial literature links depression with low-grade systemic inflammation in at least a subset of patients. Increased concentrations of inflammatory mediators such as CRP, IL-6 and TNF-alpha have been associated with depressive symptoms in observational and mechanistic studies, although these biomarkers are not diagnostic of depression and vary with obesity, infection, chronic disease, sleep and other factors. Omega-3 fatty acids can alter the production of lipid mediators and may shift inflammatory signaling toward resolution rather than simply blocking one inflammatory pathway.[9,10]

Neurotransmitter Systems

Depression involves networks regulating serotonin, norepinephrine, dopamine, glutamate and GABA. Omega-3 fatty acids may influence receptor function, membrane microdomains, vesicle trafficking and second-messenger signaling. These effects are biologically plausible but should not be simplified to "omega-3 raises serotonin." Clinical antidepressant action is likely to arise from multiple interacting pathways.[9,13,14]

HPA-Axis and Stress Biology

Chronic stress may activate the HPA axis, alter cortisol rhythms and influence hippocampal and prefrontal function. Experimental literature suggests that omega-3 status can affect stress responsiveness and neuroendocrine signaling. However, effects vary by dose, baseline nutritional state and model, and human clinical evidence linking HPA normalization directly to symptom improvement is still limited.[9,24]

Oxidative Stress and Mitochondria

Oxidative stress has been proposed as a contributor to neuronal dysfunction in depression. Omega-3 fatty acids can influence redox signaling and membrane composition, but the chemistry is complex because polyunsaturated fatty acids themselves are prone to oxidation. The biologic effect therefore depends on the balance between controlled lipid signaling, antioxidant defenses and product quality.[9,31]

Neuroplasticity and BDNF

Brain-derived neurotrophic factor (BDNF) supports neuronal survival, synaptic plasticity and learning-related processes. Meta-analytic evidence from controlled trials suggests omega-3 supplementation can raise circulating BDNF, although heterogeneity is high and peripheral BDNF is an imperfect surrogate for brain BDNF. This pathway is therefore promising but not sufficient by itself to prove antidepressant efficacy.[11,12]

ISSN 2583-2069

Interaction with Antidepressant and Other Psychotropic Treatments

Table 5: Potential Interactions of Omega-3 Fatty Acids with Antidepressant and Other Psychotropic Treatments

Drug class	Pathophysiological target	Interaction with omega-3
SSRIs, e.g., fluoxetine and sertraline	Serotonin reuptake inhibition → increased synaptic serotonin	Omega-3 may influence membrane properties and signaling and may provide adjunctive effects[5,13]
SNRIs, e.g., venlafaxine and duloxetine	Increased serotonin and norepinephrine signaling	Omega-3 may complement neurotransmitter-related signaling[13,14]
Atypical antidepressants, e.g., bupropion and mirtazapine	Dopaminergic/noradrenergic and other mechanisms	Potential complementary neuroprotective and signaling effects; clinical evidence remains limited[13,14]
Mood stabilizers, e.g., lithium and valproate	Neuroprotective and intracellular signaling effects	Omega-3 has overlapping anti-inflammatory and neurotrophic mechanisms, but evidence for specific combinations is limited[30]
Antipsychotics	Dopamine receptor modulation	Omega-3 has been investigated as adjunctive therapy, but evidence should not be generalized to prevention of all antipsychotic adverse effects[9]

Proposed Mechanisms of Antidepressant Action

The antidepressant hypothesis for omega-3s is best understood as a network model rather than a single receptor mechanism. EPA and DHA can modify neuronal and immune cell membranes, change precursor availability for lipid mediators, influence intracellular signaling, and interact with neuroendocrine and metabolic systems. These mechanisms are complementary and may be particularly relevant in inflammatory or treatment-resistant subgroups.[9,24]




Figure 2: Simplified schematic representation of the proposed mechanisms underlying the antidepressant effects of omega-3 fatty acids (EPA and DHA)

Table 6: Proposed Mechanisms of Action of Omega-3 Fatty Acids in Depression

Mechanism	Proposed action	Potential clinical relevance	Strength of evidence
Membrane effects	DHA contributes to membrane structure and influences receptor and signaling microdomains	May support efficient neurotransmission and synaptic function	Biologically strong; clinical mediation evidence limited[9]
Inflammatory modulation	EPA competes with arachidonic-acid pathways and generates lipid mediators; n-3s can influence inflammatory markers	May help patients with inflammation-associated depressive symptoms	Moderate mechanistic and clinical support[10,13,14]
Resolution pathways	EPA/DHA are precursors to specialized pro-resolving mediators	May help terminate rather than merely suppress inflammatory responses	Promising; human depression data still developing[9,24]
Neurotransmission	May modify serotonin, dopamine and glutamate/GABA-related signaling indirectly through membranes and signaling pathways	Potential additive effect with antidepressants	Plausible; direct clinical mediation uncertain[13,14]
BDNF/ neuroplasticity	May influence BDNF-related and synaptic plasticity pathways	Could support recovery of cognitive and affective networks	Supported by biomarker meta-analyses; causality uncertain[11,12]
HPA-axis	May alter stress reactivity and cortisol signaling	Potential reduction of stress-related amplification of symptoms	Preclinical and limited human support[9,24]
Oxidative stress	May influence lipid peroxidation and antioxidant responses	Potential neuronal protection	Mechanistic evidence; product oxidation is a countervailing concern[9,31]
Gut-brain axis	May affect microbiota composition, gut barrier and microbial signaling	Possible influence on inflammation and neuroactive metabolites	Emerging area; clinical evidence preliminary[24]

Recent reviews increasingly describe omega-3s as "network modulators." Reviews have summarized effects on neuroinflammation, neurotransmitter function, neuroplasticity, the gut-brain axis, membrane signaling, HPA-axis regulation and oxidative stress [9,24]. These mechanistic models are useful for generating hypotheses, but biological plausibility does not automatically establish clinical benefit for every depressed patient.

Clinical Evidence for Omega-3 Supplementation

Observational and Ecological Evidence

Early interest was supported by ecological observations linking higher fish consumption with lower population rates of depression. Such findings are useful for hypothesis generation but are vulnerable to confounding by overall dietary pattern, socioeconomic status, lifestyle, healthcare access and cultural factors. They cannot establish that fish oil itself prevents or treats depression.[13,35]

Randomized Trials of Monotherapy

Several small randomized trials have evaluated purified EPA or DHA as monotherapy. A 2015 double-blind trial comparing EPA-enriched and DHA-enriched preparations in adults with MDD found improvement within all groups but neither active preparation separated significantly from placebo.[15] An earlier DHA monotherapy trial also did not show a statistically significant antidepressant effect. These studies illustrate a key limitation of the literature: even when omega-3 has biologic activity, monotherapy trials may fail to show a clinical advantage because of placebo response, small sample size, baseline nutritional status or inadequate subgroup targeting.[15,22] A 2022 review focused specifically on omega-3 monotherapy concluded that available randomized evidence did not justify recommending omega-3 PUFAs as standalone treatment for MDD.[22] This aligns with the broader consensus that omega-3s should not displace established depression treatments when those treatments are indicated.[2,5]

ISSN 2583-2069

Adjunctive Therapy with Antidepressants

The adjunctive strategy has generally produced more encouraging results. In the 2016 meta-analysis restricted to adults with clinically diagnosed MDD, omega-3 supplementation had an overall beneficial effect, and higher EPA exposure and concurrent antidepressant use were associated with better outcomes in meta-regression.[13] This pattern is consistent with the hypothesis that EPA may enhance or complement antidepressant therapy in selected patients rather than act as a full substitute for standard pharmacotherapy.

Clinical trials have not been uniformly positive. A large Canadian randomized trial using a predominantly EPA formulation did not reach its primary endpoint overall, although subgroup analyses suggested differential effects in participants with comorbid anxiety.[23] Another trial in outpatients receiving sertraline investigated adjunctive omega-3s and reported favorable effects on several psychological outcomes, but the broader evidence base remains mixed.[16,17]

EPA versus DHA

The literature repeatedly suggests that EPA is more closely associated with antidepressant efficacy than DHA, especially when omega-3 is used as an adjunct. A classic 2007 meta-analysis and subsequent meta-analyses found evidence supporting an antidepressant effect of omega-3 fatty acids, with later analyses indicating that EPA-predominant preparations may be more consistently associated with benefit.[36,13,14] A 2019 meta-analysis reported clinical benefit in EPA-pure or EPA-major formulations, whereas DHA-major preparations were less convincing.[14] The 2019 ISNPR practice guideline consequently emphasized pure EPA or EPA/DHA combinations in which EPA predominates.[5]

DHA remains biologically important because it is highly concentrated in neuronal membranes and contributes to membrane organization and synaptic function.[9] The fact that DHA-alone trials are inconsistent does not imply DHA has no role in brain health. Instead, the available evidence suggests that EPA may be the more directly useful component when the clinical endpoint is depressive symptom reduction.[14,15]

Depression Prevention versus Treatment

A key distinction is whether omega-3 is being studied to prevent depression in people without depression or to reduce symptoms in people who already have depression. Preventive trials have often been neutral or inconclusive [35]. The 2024 dose-response meta-analysis specifically found no convincing reduction in incident depression in the general adult population.[3] By contrast, treatment trials in people with established depressive symptoms more often demonstrate a small average symptom improvement.[2-4] Thus, evidence for prevention should not be conflated with evidence for treatment.

Treatment-Resistant Depression

Treatment-resistant depression is another area of interest because anti-inflammatory and membrane-based mechanisms may be especially relevant when conventional antidepressant response is incomplete. Reviews of the available literature have described encouraging findings for EPA-predominant formulations in treatment-resistant depression, while also emphasizing the need for better trials.[9,18] This body of evidence is promising but not yet sufficient to establish a standardized treatment protocol.

Dose, EPA/DHA Ratio and Formulation Considerations

Dose is one of the most difficult issues in interpreting omega-3 depression research because "omega-3 dose" may mean total fish oil, total EPA+DHA, EPA alone or DHA alone. These are not equivalent. A capsule containing 1,000 mg of fish oil may contain only a few hundred milligrams of EPA+DHA. Academic reports should therefore describe the exact amount of EPA and DHA rather than only total oil weight.[5,31]

The 2019 ISNPR practice guideline recommended 1-2 g/day of net EPA, using either pure EPA or an EPA/DHA combination with an EPA:DHA ratio above 2:1, as an adjunctive strategy in MDD [5]. Later meta-analyses have not produced a single universally accepted dose. The 2024 dose-response synthesis suggested the strongest average symptom signal near 1.5 g/day total n-3s in established depression.[3] while the 2025 analysis suggested a possible benefit profile around 1,000-1,500 mg/day with EPA: DHA between 1:1 and 2:1 in a specific subgroup.[4] These apparently different estimates demonstrate that dose optimization remains unresolved.

Safety, Adverse Effects and Drug Interactions

Omega-3 supplements are generally well tolerated at commonly studied doses. Frequently reported adverse effects are mild and include unpleasant taste, fishy aftertaste, bad breath, heartburn, nausea, abdominal discomfort, diarrhea and headache.[31] Taking the supplement with food and using divided doses can reduce gastrointestinal symptoms for some people.

Bleeding is a common concern because omega-3 fatty acids can have antiplatelet effects. Current evidence summarized by the U.S. National Institutes of Health Office of Dietary Supplements indicates that long-term combined EPA+DHA intake up to about 5 g/day appears safe for most adults and that clinically significant bleeding has generally not been demonstrated at commonly studied doses [31]. However, individuals taking anticoagulant or antiplatelet medicines should discuss use with a clinician and may require monitoring, especially with higher doses or multiple agents affecting hemostasis.[31,32] Atrial fibrillation deserves separate attention. NIH ODS notes that two large cardiovascular

trials using 4 g/day omega-3 for several years found a small increase in atrial fibrillation risk among people with cardiovascular disease or high cardiovascular risk.[31] These cardiovascular trials used doses and populations different from typical depression adjunctive studies, so the finding should not be directly extrapolated to every patient using a lower psychiatric dose, but it reinforces the importance of avoiding unnecessary high-dose self-medication.

The pharmacist should also identify pregnancy, surgery planning, bleeding disorders, use of anticoagulants/antiplatelets, significant arrhythmia history and concurrent supplements that may influence bleeding [31,32]. A patient should be advised to seek professional guidance rather than treating persistent or severe depressive symptoms solely with a nutritional supplement.

Table 7: Omega-3 Formulation Factors, Their Clinical Relevance, and Practical Pharmacy Considerations

Formulation factor	Relevance	Practical pharmacy point
Total oil vs EPA+DHA	Total fish oil can greatly exceed active omega-3 content	Calculate actual EPA + DHA per daily dose[31]
EPA:DHA ratio	Clinical studies suggest greater consistency with EPA-predominant products	Read individual EPA and DHA quantities; do not infer ratio from "fish oil"[5,14]
Chemical form	Triglyceride, re-esterified triglyceride and ethyl ester forms differ in absorption characteristics	Use a reputable product and take as directed, often with a meal containing fat[31]
Oxidation/freshness	PUFAs are susceptible to oxidation	Check manufacturer quality, storage instructions, expiry and packaging[31]
Dose frequency	Large doses can be divided to improve gastrointestinal tolerance	Follow studied or prescribed daily amount rather than escalating independently
Purity	Contaminants and concentration vary between products	Prefer quality-assured products with independent testing when available[31]

Table 8: Safety Issues Associated with Omega-3 Supplementation and Recommended Pharmacy Actions

Safety issue	What is known	Pharmacy action
GI intolerance	Common, usually mild [31]	Take with food; consider dose splitting; assess adherence
Bleeding/anticoagulants	High doses have antiplatelet potential; clinically significant bleeding is uncommon at standard doses[31,32]	Review warfarin/anticoagulants/antiplatelets; advise clinician review for high-dose use
Atrial fibrillation	Small increased risk reported with 4 g/day cardiovascular dosing in high-risk populations[31]	Avoid assuming more is better; assess cardiovascular history
Fish allergy/source issues	Fish-based products may be unsuitable for some patients	Consider algae-derived options when appropriate
Oxidized product	Poorly stored PUFA may oxidize	Check expiry, storage and product quality[31]
Drug substitution	Supplements are not equivalent to antidepressant treatment	Do not advise discontinuation of prescribed antidepressants solely because omega-3 is added

ISSN 2583-2069

Special Populations

Older Adults and Dementia

Older adults may have depression related to medical illness, bereavement, neurodegenerative disease, medication effects or social factors. A 2024 systematic review and meta-analysis examined omega-3 supplementation in older adults and people with dementia and highlighted uncertainty in the evidence.[25] Heterogeneity in diagnosis, formulation and outcome measures makes a universal conclusion difficult. Because older adults often use antiplatelet or anticoagulant medicines and have polypharmacy, medication review is especially important.[25,31]

Pregnancy and Perinatal Depression

Pregnancy and the postpartum period are clinically important because both maternal depression and fetal neurodevelopment matter. Meta-analyses of perinatal trials have been inconsistent. A randomized trial of omega-3 fatty acids during pregnancy investigated their effects in major depressive disorder, while subsequent systematic reviews have produced mixed findings.[19,35] Omega-3 should therefore not be presented as a proven standalone therapy for perinatal depression. Any use during pregnancy or postpartum should be integrated into obstetric and mental-health care.[19]

Children and Adolescents

Evidence in young people is much smaller than in adults. A 2024 Cochrane review addressed omega-3 supplementation for depression in children and adolescents and emphasized the limited certainty of the evidence base.[26] Because pediatric depression can be associated with suicide risk and rapid clinical change, supplement counselling must never delay formal assessment and evidence-based psychological or pharmacological care.

Comorbid Medical Disease and Inflammation

Inflammation may identify a biologically interesting subgroup. A randomized dose-finding trial in adults with MDD, overweight/obesity and elevated hs-CRP compared 1, 2 and 4 g/day EPA with placebo. In that small study, 4 g/day EPA showed a numerically higher response rate than placebo, but the primary inflammatory biomarker endpoints were not robustly improved across doses.[23] The study supports further biomarker-guided research rather than a routine recommendation for high-dose EPA.

Pharmacy Practice and Patient Counselling

Omega-3 depression research has direct relevance to pharmacy because product selection, dose verification, adherence, interactions and patient expectations strongly influence safe use. Pharmacists should approach omega-3 as a complementary intervention whose evidence is strongest in selected adjunctive contexts, not as a replacement for psychiatric assessment.[2,5]

What the Pharmacist Should Assess

- Current diagnosis or symptoms, duration and severity, including whether the patient is already receiving antidepressant or psychological treatment
- Exact supplement label: EPA per capsule, DHA per capsule, number of capsules per day and total EPA+DHA per day[31]
- Concomitant medicines, particularly warfarin and other anticoagulant or antiplatelet drugs[31,32]
- History of atrial fibrillation, major cardiovascular disease, bleeding disorders, surgery planning or significant fish allergy[31]
- Adherence, gastrointestinal adverse effects, storage conditions and whether the product is being used consistently
- Patient expectations: clarify that omega-3 may provide a modest adjunctive benefit and is not an emergency treatment for suicidal thoughts or severe depression[2,5]

Simple Patient Counselling Points

- Check the EPA and DHA amounts on the label. "1000 mg fish oil" does not mean 1000 mg EPA+DHA[31]
- Use the planned daily dose consistently and do not increase the dose simply because symptoms have not improved quickly
- Taking the capsules with food may improve tolerability and absorption[31]
- Continue prescribed antidepressant or psychotherapy unless the treating clinician advises otherwise
- Report unusual bruising, bleeding, palpitations or severe gastrointestinal symptoms, especially if other medicines are being taken
- For worsening depression, self-harm thoughts or suicidal thoughts, seek urgent mental-health care rather than relying on supplementation

Formulation Quality and Pharmaceutical Relevance

From a pharmaceutical science perspective, omega-3 supplements create challenges related to oxidation, encapsulation, flavor masking, dose uniformity, bioavailability and stability. Reproducible clinical research requires pharmaceutical-grade characterization of the intervention. Future formulations could benefit from standardized EPA concentration, improved oxidation control, better patient-centered dosing and quality verification that clearly reports EPA and DHA content.[31,33]

Limitations of Current Evidence

The most important limitation is heterogeneity. "Omega-3 supplementation" is not a single intervention. Trials vary in total dose, EPA/DHA ratio, chemical form, duration and placebo. Depression itself is heterogeneous, and participants differ in age, baseline inflammation, dietary fish intake, omega-3 status, illness severity, comorbidity and background antidepressant use.[2-4,13,14] Placebo selection

is a particular methodological issue. Oils used as controls may themselves have metabolic or inflammatory effects, and fishy taste can threaten blinding. Small samples and high placebo response can make modest between-group effects difficult to detect. Different rating scales, diagnostic criteria and definitions of response and remission further reduce comparability.[2,13,14,33] Publication bias is another recurring concern. Some meta-analyses report a favorable pooled effect, but the magnitude can shrink when small studies or possible publication bias are considered [4,7,14]. Meta-regression and subgroup findings can suggest who might respond, but these are observational patterns within aggregated studies and should be treated as hypothesis-generating until prospectively tested. Another limitation is overinterpretation of biomarkers. Changes in CRP, BDNF or inflammatory cytokines may support mechanism but do not necessarily translate into clinically meaningful symptom improvement. Likewise, changes in blood fatty-acid levels show biological exposure but do not prove that the brain has received a therapeutically relevant dose.[10-12]

Future Research Directions

Personalized Nutrition and Precision Psychiatry

Future research should integrate genetic, inflammatory and lipidomic profiling to identify which patients respond best to omega-3 therapy. Development of biomarker-guided supplementation based on baseline EPA/DHA status, omega-3 index and inflammatory markers may help identify clinically relevant subgroups.[29,33]

Adjunctive Treatment Strategies

Future trials should investigate omega-3s in combination with antidepressants, psychotherapy or other interventions. Particular attention may be given to EPA-dominant formulations in treatment-resistant or inflammation-associated depression.[5,18,33]

Neuroimaging and Mechanistic Studies

fMRI, PET and molecular studies could help characterize changes in brain connectivity, neurotransmitter systems, microglial activity and synaptic remodeling following omega-3 supplementation.[9,24]

Gut-Brain Axis Exploration

Research should investigate how omega-3 fatty acids alter gut microbiota composition, intestinal barrier function and microbial metabolite signaling in depressive disorders. Combined probiotic and omega-3 approaches may also warrant controlled investigation.[24]

Life-Stage and Sex-Specific Research

Further studies are needed across adolescents, perinatal populations and older adults because hormonal, metabolic and developmental factors may influence omega-3 metabolism and treatment response.[19,25,26]

Research Gaps

Table 9: Research Gaps and Future Directions in Omega-3 Fatty Acid Research for Depression

Area	Current limitation	Needed advancement
Dose optimization	No consensus on ideal EPA:DHA ratio or duration	Standardized dosing trials[3-5]
Mechanistic clarity	Molecular pathways linking omega-3 to neurotransmission remain incompletely understood	Multi-omics and neuroimaging studies[9,24]
Clinical heterogeneity	Mixed results across populations	Stratified trials according to inflammation, omega-3 status and other characteristics[4,33]
Long-term outcomes	Few studies beyond 6-12 months	Longitudinal follow-up assessing maintenance and recurrence[33]
Combination therapies	Limited data on synergy with SSRIs or CBT	Controlled adjunctive therapy trials[5,13]
Gut-brain research	Early clinical evidence	Integrative microbiome and metabolomic studies[24]

ISSN 2583-2069

Emerging Directions

Emerging research areas include nanotechnology-based delivery systems to improve omega-3 bioavailability, epigenetic studies examining effects on gene expression related to mood regulation, and digital health approaches for monitoring symptoms during supplementation.[9,24,33] Omega-3 research is increasingly moving toward a systems-biology approach connecting diet, inflammation, neuroplasticity and mental health. Future studies should determine whether these biological characteristics can be translated into clinically useful precision approaches. Future clinical trials should use standardized, pharmaceutical-grade EPA/DHA preparations with transparent reporting of exact EPA and DHA content, chemical form, oxidation status and adherence [31,33]. Researchers should pre-specify clinically important outcomes such as remission, functioning and quality of life rather than relying only on symptom-scale changes. Trials should also consider baseline omega-3 index, inflammatory markers, metabolic status, obesity and antidepressant use as potential effect modifiers.[3,4,29,33] Future studies should compare EPA-pure, EPA-predominant and balanced EPA/DHA formulations at clearly defined doses and use placebo oils that preserve blinding without introducing major biological effects. Adequate sample sizes, preregistration, transparent reporting and longer follow-up are required to assess maintenance, recurrence and adverse effects.[33] Mechanistic studies should further investigate specialized pro-resolving lipid mediators, endocannabinoid signaling, mitochondrial function, neuroplasticity and gut-brain mechanisms as potential mediators of treatment response.[9,24] Additional research should determine whether omega-3 supplementation has different effects in treatment-resistant depression, late-life depression, inflammatory depression and depression associated with cardiometabolic disease.Pharmaceutical research should also focus on pharmacy-friendly formulations with high concentration, low oxidation, good palatability and clear dosing instructions.[31,33]

Discussion

Depression is a complex and multifactorial psychiatric disorder involving interactions among genetic, neurochemical, inflammatory, metabolic, and environmental factors. Although conventional antidepressant medications and psychological interventions remain the principal approaches to treatment, a considerable proportion of patients experience inadequate response, delayed improvement, residual symptoms, or adverse effects. Consequently, increasing attention has been directed toward nutritional and complementary interventions that may influence biological pathways involved in depression. Among these, omega-3 polyunsaturated fatty acids (PUFAs), particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have received considerable scientific interest because of their structural and functional roles in the central nervous system and their potential effects on inflammation, neuronal signaling, and neuroplasticity.[9,24]

The findings of the present study indicate that omega-3 fatty acid supplementation may produce a small-to-moderate improvement in depressive symptoms in selected adults, although the magnitude and consistency of the effect vary considerably among studies. This finding provides partial support for the potential antidepressant role of omega-3 fatty acids but also demonstrates that the response is not uniform across all patients or formulations. The biological plausibility of this effect is supported by the involvement of EPA and DHA in neuronal membrane structure, membrane fluidity, neurotransmitter signaling, inflammatory regulation, oxidative processes, and neuroplasticity.[9,24] DHA is an important structural component of neuronal membranes and contributes to normal neuronal function, whereas EPA is more closely associated with the regulation of inflammatory pathways and lipid-derived signaling mediators. Alterations in membrane lipid composition and chronic low-grade inflammation have been proposed as potential contributors to depressive disorders, providing a rationale for evaluating omega-3 fatty acids as therapeutic or adjunctive interventions.

One of the most important observations from the available evidence is the possible difference between EPA-predominant and DHA-predominant formulations. Several systematic reviews and meta-analyses have suggested that EPA-containing or EPA-predominant preparations may provide greater improvement in depressive symptoms than DHA-predominant formulations.[3-5] In the context of the present study, this pattern suggests that EPA may be a principal contributor to the observed antidepressant effect, while DHA may provide complementary structural and neurobiological functions. EPA can influence the production of inflammatory lipid mediators and may reduce pro-inflammatory signaling, whereas DHA has a more prominent structural role within neuronal membranes.[9,24] Neuroinflammation has increasingly been investigated as a component of depression pathophysiology, and EPA-mediated modulation of inflammatory processes may therefore contribute to its potential antidepressant effects.

However, the evidence does not establish that EPA is universally superior to DHA. Differences in study populations, EPA:DHA ratios, doses, treatment duration, depression severity, concomitant medications, and outcome measures may contribute to the variation among clinical trials. Therefore, the apparent advantage of EPA-predominant formulations should be interpreted as a clinically relevant trend rather than an established rule applicable to every patient with depression.

The role of omega-3 fatty acids as an adjunctive treatment is particularly noteworthy. Evidence appears to be more supportive when omega-3 supplementation is administered in combination with conventional antidepressant therapy

than when it is used as monotherapy.[3-5] Patients who achieve only a partial response to antidepressants may represent an important population for adjunctive omega-3 therapy. The potential benefit of combining omega-3 fatty acids with antidepressants may involve complementary mechanisms, with conventional antidepressants primarily influencing monoaminergic neurotransmission while omega-3 fatty acids may additionally affect inflammatory, membrane, metabolic, and neuroplasticity-related pathways. Therefore, the findings of this study support the potential role of omega-3 fatty acids as a complementary intervention, particularly in patients with an incomplete response to standard therapy.

In contrast, evidence supporting omega-3 fatty acids as monotherapy remains comparatively uncertain.[3-5] Similarly, findings concerning the prevention of depressive disorders are less consistent than those observed in patients with established depressive symptoms.[13,14,22] Thus, omega-3 supplementation should not be interpreted as a universal replacement for antidepressant medication or psychotherapy. Patients with clinically significant depression should continue to receive appropriate professional assessment and evidence-based treatment.

Dose appears to be another important determinant of the therapeutic response. Recent dose-response evidence has suggested that the greatest average improvement in depressive symptoms may occur at approximately 1.5 g/day of total omega-3 fatty acids among adults with established depression.[3] Similarly, another recent meta-analysis reported a potentially favorable range of approximately 1,000–1,500 mg/day, with an EPA:DHA ratio of approximately 1:1 to 2:1 in a specific patient subgroup.[4] These findings suggest that therapeutic effects may occur within a particular exposure range rather than increasing proportionally with dose. However, the findings should not be interpreted as establishing a single optimal dose for every patient because the included studies differed in formulation, treatment duration, population characteristics, baseline omega-3 status, and concomitant treatment.

An important study-specific implication is that the actual EPA and DHA exposure may be more informative than the total fish-oil dose. Commercial omega-3 preparations can vary substantially in total fish-oil content, EPA and DHA concentrations, chemical form, oxidation status, excipients, and manufacturing quality.[31] A product labelled as containing 1,000 mg of fish oil does not necessarily provide 1,000 mg of combined EPA and DHA. Consequently, clinical trials and clinical practice should report and consider the individual EPA and DHA content rather than relying solely on the total fish-oil quantity. Differences in product composition may partly explain variability between clinical studies and should be considered when comparing therapeutic outcomes.

The chemical and pharmaceutical characteristics of omega-3 preparations also deserve consideration. Omega-3 fatty acids may be formulated as triglycerides, re-esterified triglycerides, phospholipids, or ethyl esters. Differences in absorption can occur according to formulation and food intake, although clinical depression trials have generally been influenced more by the actual EPA/DHA content and ratio than by the broad label term “fish oil”.[5,31] Oxidative stability is another important quality consideration because EPA and DHA contain multiple carbon-carbon double bonds and are therefore susceptible to lipid peroxidation.[31] Exposure to oxygen, heat, light, and inappropriate storage conditions may increase oxidation and compromise product quality. Appropriate packaging, storage, manufacturing controls, and independent quality testing are consequently important considerations when selecting omega-3 preparations.

Safety and patient-specific considerations should also form an essential component of omega-3 supplementation. Although omega-3 fatty acids are generally well tolerated at commonly studied doses, gastrointestinal discomfort, fishy aftertaste, nausea, and loose stools may occur. Potential bleeding-related concerns may also require consideration in individuals receiving medicines that affect hemostasis, particularly when higher doses are used.[31,32] Pharmacists and other healthcare professionals should therefore evaluate the patient’s medication profile, comorbidities, dosage, and overall treatment plan before recommending supplementation. Patients should also be advised not to independently increase the dose or discontinue prescribed antidepressant medication because of perceived benefits from omega-3 supplementation.

From a pharmacy practice perspective, pharmacists can play an important role in promoting rational and evidence-based use of omega-3 supplements. Patient counselling should include verification of the actual EPA and DHA content, recommended daily dose, formulation, storage conditions, adherence, possible adverse effects, and relevant medication-related concerns.[5,31] Pharmacists can also help patients distinguish between nutritional supplementation and therapeutic treatment. Individuals experiencing persistent, severe, or worsening depressive symptoms should be encouraged to obtain appropriate mental-health assessment rather than relying solely on dietary supplements.

The heterogeneity of the existing literature represents an important limitation when interpreting the findings of the present study. Randomized controlled trials have differed in participant characteristics, diagnostic criteria, depression severity, baseline dietary omega-3 intake, EPA:DHA composition, dosage, treatment duration, comparator groups, and outcome assessment instruments. Some studies have included patients receiving antidepressants, whereas others have evaluated omega-3 fatty acids as monotherapy. Variations in supplement purity, formulation, adherence, and reporting of EPA and DHA doses may further complicate comparisons. Small sample sizes and differences in study quality can also contribute to uncertainty in pooled estimates.

ISSN 2583-2069

These factors may explain why some clinical studies report significant antidepressant effects while others demonstrate limited or no benefit.

The findings therefore suggest that the therapeutic value of omega-3 supplementation is likely to depend on formulation, dose, EPA:DHA composition, patient characteristics, and treatment context, rather than on omega-3 supplementation as a single uniform intervention. This interpretation is important because it shifts the clinical perspective from simply recommending "fish oil" toward selecting appropriately characterized omega-3 preparations and considering patient-specific factors. The present evidence supports the hypothesis that omega-3 fatty acids can contribute to improvement in depressive symptoms in selected individuals, but it does not establish sufficient evidence for their use as universal monotherapy.

Future research should move toward greater standardization and precision-based approaches. Large, adequately powered randomized controlled trials should use chemically characterized and standardized EPA/DHA preparations and clearly report individual EPA and DHA doses, EPA:DHA ratios, treatment duration, adherence, baseline omega-3 status, and concomitant antidepressant therapy. Researchers should also consider inflammatory biomarkers, oxidative stress markers, nutritional status, and other biological characteristics that may help identify patients who are more likely to respond. Longer follow-up periods are necessary to determine the sustainability of clinical benefits and to clarify long-term safety. Well-designed subgroup analyses may further determine whether age, sex, baseline nutritional status, depression severity, inflammatory profile, or antidepressant treatment modifies the response to omega-3 supplementation.[3-5]

Overall, the present study indicates that omega-3 fatty acids, particularly EPA-containing or EPA-predominant formulations, may provide a modest therapeutic benefit for depressive symptoms in selected adults, with potentially greater utility when used as an adjunct to conventional antidepressant treatment. The findings are clinically relevant but should be interpreted cautiously because of substantial variation in dose, formulation, EPA:DHA ratio, patient characteristics, and study methodology. Omega-3 supplementation should therefore be considered a potential complementary strategy rather than a replacement for established depression management. Continued high-quality research integrating clinical, nutritional, pharmacological, and biological factors will be essential for determining which patients are most likely to benefit and for establishing the optimal formulation and dosage of omega-3 fatty acids in depression.

Conclusion

Omega-3 fatty acids, especially EPA and DHA, are biologically active nutrients with plausible roles in neuronal membrane function, inflammatory regulation, neuroplasticity and stress-related signaling.[9,24] Clinical evidence supports a modest average improvement in depressive symptoms in some adults, but the effect is not uniform and does not justify treating omega-3 as a universal replacement for antidepressant therapy or psychotherapy.[2-5] The evidence is generally more consistent for EPA-predominant formulations and for adjunctive use, whereas monotherapy and prevention findings are more uncertain.[3-5,13,14,22] Recent evidence also emphasizes dose and patient selection. A 2024 dose-response meta-analysis suggested the greatest average symptom benefit near 1.5 g/day of total n-3 fatty acids in adults with established depression,[3] while a 2025 meta-analysis identified a possible benefit profile around 1,000-1,500 mg/day with EPA:DHA 1:1 to 2:1 in a specific subgroup.[4] These findings should not be interpreted as a single universally established dose because guideline recommendations and trial results differ [4,5].In clinical practice, product quality, exact EPA/DHA content, concomitant medicines, cardiovascular and bleeding risks, and the patient's overall depression treatment plan must be considered.[31,32] For pharmacy practice, the key message is evidence-informed adjunctive use. Pharmacists can improve safe use by checking the actual EPA+DHA dose, identifying interactions, counselling about adherence and adverse effects, preventing unsafe dose escalation, and ensuring that patients with significant depression receive appropriate professional mental-health care.[5,31] Future research should move toward standardized formulations and precision approaches that identify which patients are most likely to benefit from omega-3 supplementation. Better-designed trials incorporating standardized EPA/DHA preparations, clinically meaningful endpoints, baseline omega-3 status, inflammatory biomarkers, longer follow-up and adequately powered subgroup analyses will be important for establishing the clinical role of omega-3 fatty acids in depression.[3,4,33]

Conflicts of Interest

None

References

1. World Health Organization. Depressive disorder (depression). Geneva: WHO; 11 September 2026.
2. Appleton KM, Voyias PD, Sallis HM, Dawson S, Ness AR, Churchill R, Perry R. Omega-3 fatty acids for depression in adults. Cochrane Database Syst Rev. 2021;11:CD004692. doi:10.1002/14651858.CD004692.pub5.
3. Norouziasl R, Zeraattalab-Motlagh S, Jayedi A, Shab-Bidar S. Efficacy and safety of n-3 fatty acids supplementation on depression: a systematic review and dose-response meta-analysis of randomised controlled trials. Br J Nutr. 2024;131(4):658-671. doi:10.1017/S0007114523002052.
4. Kong L, Zhang Q, Wang H, Xu Y, Xu C, Chen Y, Lu J, Hu S. Exploration of the optimized portrait

of omega-3 polyunsaturated fatty acids in treating depression: a meta-analysis of randomized-controlled trials. J Affect Disord. 2025;379:489-501. doi:10.1016/j.jad.2025.03.006.
5. Guu TW, Mischoulon D, Sarris J, Hibbeln J, McNamara RK, Hamazaki K, Freeman MP, Maes M, Matsuoka YJ, Belmaker RH, Jacka F, Pariante C, Berk M, Marx W, Su KP. International Society for Nutritional Psychiatry Research practice guidelines for omega-3 fatty acids in the treatment of major depressive disorder. Psychother Psychosom. 2019;88(5):263-273. doi:10.1159/000502652.
6. Su KP, Tseng PT, Lin PY, Okubo R, Chen TY, et al. A multi-national, multi-disciplinary Delphi consensus study on using omega-3 polyunsaturated fatty acids for the treatment of major depressive disorder. Psychother Psychosom. 2020.
7. Lu Y, Qiao D, Mi G. Clinical impacts of n-3 fatty acids supplementation on depression symptoms: an umbrella review of meta-analyses. Br J Nutr. 2024;131(5):841-850. doi:10.1017/S000711452300226X.
8. Kelaiditis CF, Gibson EL, Dyall SC. Effects of long-chain omega-3 polyunsaturated fatty acids on reducing anxiety and/or depression in adults: a systematic review and meta-analysis of randomised controlled trials. Prostaglandins Leukot Essent Fatty Acids. 2023;192:102572. doi:10.1016/j.plefa.2023.102572.
9. Serefko A, Jach ME, Pietraszuk M, Swiąder M, Swiąder K, Szopa A. Omega-3 polyunsaturated fatty acids in depression. Int J Mol Sci. 2024;25(16):8675. doi:10.3390/ijms25168675.
10. Kavyani Z, Musazadeh V, Fathi S, Faghfouri AH, Dehghan P, Sarmadi B. Efficacy of the omega-3 fatty acids supplementation on inflammatory biomarkers: an umbrella meta-analysis. Int Immunopharmacol. 2022;111:109104. doi:10.1016/j.intimp.2022.109104.
11. Ziaei S, Mohammadi S, Hasani M, Morvaridi M, Belancic A, Daneshzad E, Saleh SAK, Adly HM, Heshmati J. A systematic review and meta-analysis of the omega-3 fatty acids effects on brain-derived neurotrophic factor (BDNF). Nutr Neurosci. 2024;27(7):715-725. doi:10.1080/1028415X.2023.2245996.
12. Hekmatdoost A, et al. Changes in serum brain-derived neurotrophic factor following supplementation of omega 3 fatty acids: a systematic review and meta-regression analysis. Clin Nutr ESPEN. 2023. doi:10.1016/j.clnesp.2023.05.019.
13. Mocking RJT, Harmsen I, Assies J, Koeter MWJ, Ruhé HG, Schene AH. Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl Psychiatry. 2016;6:e756. doi:10.1038/tp.2016.29.
14. Liao Y, Xie B, Zhang H, He Q, Guo L, Subramanieapillai M, Fan B, Lu C, McIntyre RS. Efficacy of omega-3 PUFAs in depression: a meta-analysis. Transl Psychiatry. 2019;9:190. doi:10.1038/s41398-019-0515-5.
15. Mischoulon D, Nierenberg AA, Schettler PJ, Kinkead B, Fehling K, Martinson MA, Rapaport MH. A double-blind, randomized controlled clinical trial comparing eicosapentaenoic acid versus docosahexaenoic acid for depression. J Clin Psychiatry. 2015;76(1):54-61. doi:10.4088/JCP.14m08986.
16. Lespérance F, Frasure-Smith N, St-André E, Turecki G, Lespérance P, Wisniewski SR. The efficacy of omega-3 supplementation for major depression: a randomized controlled trial. J Clin Psychiatry. 2011;72(8):1054-1062. doi:10.4088/JCP.10m05966blu.
17. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry. 2002;159(3):477-479.
18. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry. 2002;59(10):913-919.
19. Su KP, Huang SY, Chiu TH, Huang KC, Huang CL, Chang HC, Pariante CM. Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008;69(4):644-651. doi:10.4088/jcp.v69n0418.
20. Mischoulon D, Freeman MP. Omega-3 fatty acids in psychiatry. Psychiatr Clin North Am. 2013;36(1):15-23.
21. Hallahan B, Ryan T, Hibbeln JR, Murray IT, Glynn S, Ramsden CE, SanGiovanni JP, Davis JM. Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression. Br J Psychiatry. 2016;209(3):192-201. doi:10.1192/bjp.bp.114.160242.
22. Accinni T, Panfili M, Tarsitani L, Biondi M, Pasquini M, Maraone A. A revision on the effectiveness of omega-3 polyunsaturated fatty acids as monotherapy in the treatment of major depressive disorder. Int J Clin Pract. 2022;2022:3801235. doi:10.1155/2022/3801235.
23. Chang JPC, Chang SS, Yang HT, Chen HT, Chien YC, Yang B, Su H, Su KP. Omega-3 polyunsaturated fatty acids in cardiovascular diseases comorbid major depressive disorder: results from a randomized controlled trial. Brain Behav Immun. 2020;85:14-20. doi:10.1016/j.bbi.2019.03.012.
24. De Cillis F, Begni V, Genini P, Leo D, Riva MA, Cattaneo A. Restoring balance: the role of omega-3 polyunsaturated fatty acids on the gut-brain axis and other interconnected biological pathways to improve depression. Nutrients. 2025;17(21):3426. doi:10.3390/nu17213426.
25. Chang YY, Ting B, Chen DTL, Hsu WT, Lin SC, Kuo CY, Wang MF. Omega-3 fatty acids for depression in the elderly and patients with dementia: a systematic review and meta-analysis. Healthcare (Basel). 2024;12(5):536. doi:10.3390/healthcare12050536.

26. Campisi SC, et al. Omega-3 fatty acid supplementation for depression in children and adolescents. Cochrane Database Syst Rev. 2024. doi:10.1002/14651858.CD014803.pub2.
27. Ravi S, Khalili H, Abbasian L, Arbabi M, Ghaeli P. Effect of omega-3 fatty acids on depressive symptoms in HIV-positive individuals: a randomized, placebo-controlled clinical trial. Ann Pharmacother. 2016;50(10):797-807. doi:10.1177/1060028016656017.
28. Shinto L, Marracci G, Mohr DC, Bumgarner L, Murchison C, Senders A, Bourdette D. Omega-3 fatty acids for depression in multiple sclerosis: a randomized pilot study. PLoS One. 2016;11(1):e0147195. doi:10.1371/journal.pone.0147195.
29. Carney RM, Steinmeyer BC, Freedland KE, Rubin EH, Rich MW, Harris WS. Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. J Clin Psychiatry. 2016;77(2):e138-e143. doi:10.4088/JCP.14m09660.
30. Kishi T, Sakuma K, Okuya M, Ikeda M, Iwata N. Omega-3 fatty acids for treating residual depressive symptoms in adult patients with bipolar disorder: a systematic review and meta-analysis of double-blind randomized, placebo-controlled trials. Bipolar Disord. 2021. doi:10.1111/bdi.13115.
31. National Institutes of Health, Office of Dietary Supplements. Omega-3 Fatty Acids - Health Professional Fact Sheet. Updated/accessed September 2026.
32. U.S. Food and Drug Administration. Petition for a Health Claim for Eicosapentaenoic Acid and Docosahexaenoic Acid. FDA safety review regarding EPA+DHA intakes and bleeding. Washington, DC: FDA.
33. Marx W, et al. Methodological and reporting recommendations for clinical trials in nutritional psychiatry: guidelines from the International Society for Nutritional Psychiatry Research. Br J Nutr. 2024;135(6):1-13. doi:10.1017/S0007114524001946.
34. Young AS, et al. Psychoeducational psychotherapy and omega-3 supplementation improve co-occurring behavioral problems in youth with depression: results from a pilot RCT. J Abnorm Child Psychol. 2017;45:1341-1352. doi:10.1007/s10802-016-0203-3.
35. Bosman XA, et al. Omega-3 and polyunsaturated fat for prevention of depression and anxiety symptoms: systematic review and meta-analysis of randomised trials. Br J Psychiatry. 2019. doi:10.1192/bjp.2019.234.
36. Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry. 2007;68(7):1056-1061. doi:10.4088/jcp.v68n0712.